Hand protection company SHOWA Group reported on Thursday the receipt of the US FDA's 510(k) medical approval for its Class I Medical device, M7005PF single-use first biodegradable nitrile gloves for medical use.
Based on the SHOWA's Eco Best Technology (EBT), M7005PF is fully biodegradable, breaking down by 82% in just 386 days when tested in a laboratory. The gloves' additional key product benefits and features include increased dexterity and flexibility, powder-free, excellent tensile strength, no natural rubber allergy risks as well as leak and tear resistant.
Following the US FDA 510(k) approval, the hospitals, Group Purchasing Organizations (GPOs) and other healthcare buyers can purchase the company's medical gloves certified as safe and effective for frontline workers.
At the Fayette, Alabama manufacturing facility, the company will increase its annual domestic production capacity to 1.2bn gloves by the end of 2022 and 2.8bn gloves once the buildout is complete. The expansion strengthens the country's domestic supply of medical PPE and reduces reliance on overseas PPE to ensure the US is better prepared for future pandemics.
AstraZeneca wins US FDA approval for Tezspire in chronic rhinosinusitis with nasal polyps
ALK partners with GenSci to expand allergy immunotherapy market in China
Ionis publishes positive Phase 3 data supporting donidalorsen as HAE prophylactic
Blacksmith Medicines granted US patent for antibacterial compounds targeting LpxC
Alvotech reports positive topline results for Xolair biosimilar study
DBV Technologies secures up to USD306.9m to advance Viaskin peanut patch programme
Celltrion's OMLYCLO receives US FDA approval
Kenox Pharmaceuticals partners with Lactiga US
Health Canada approves ALK's ACARIZAX for young children with dust mite allergy
Allergy Therapeutics publishes positive Phase III data for Grass MATA MPL
CSL's ANDEMBRY receives European approval to prevent attacks of hereditary angioedema
NICE recommends ALK's ACARIZAX for house dust mite allergic rhinitis treatment in UK's NHS
European Commission approves Palforzia for toddlers with peanut allergy